Related Experiment Video

Updated: Jun 15, 2026

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
09:45

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

Potential targets for improving radiosensitivity of breast tumor-initiating cells

Wei Xu1, Bisrat G Debeb, Lara Lacerda

  • 1Division of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.

Anti-Cancer Agents in Medicinal Chemistry
|February 27, 2010
PubMed

Insights

Tumor-initiating cells (TICs) resist radiation therapy, driving cancer recurrence. Researchers are exploring novel radiosensitizers to target these cells, aiming to improve patient outcomes and reduce cancer recurrence after radiation treatment.

Area of Science:

  • Oncology
  • Cancer Biology
  • Radiation Oncology

Background:

  • A subset of cells, tumor-initiating cells (TICs), are implicated in therapy resistance and cancer recurrence.
  • Breast cancer TICs are a focus due to their potential role in radioresistance and survival.

Purpose of the Study:

  • To review current strategies for identifying and targeting breast cancer TICs.
  • To discuss novel agents and existing therapies for radiosensitizing TICs.
  • To explore methods for improving clinical outcomes and reducing cancer recurrence post-radiation.

Main Methods:

  • Literature review of recent studies on TICs and radiosensitization.
  • Exploration of various targets and therapeutic approaches for TICs.
  • Analysis of novel compounds and current clinical therapies for TIC radiosensitization.

Main Results:

  • Numerous targets are under investigation for their role in TIC self-renewal, survival, and radioresistance.
  • Development of novel radiosensitizers is ongoing to improve therapeutic efficacy.
  • Current therapies are being evaluated for their potential to radiosensitize TICs.

Conclusions:

  • Targeting TICs is a promising strategy to overcome therapy resistance and prevent cancer recurrence.
  • Novel radiosensitizers and repurposed existing therapies hold potential for enhancing radiation treatment outcomes.
  • Further research is crucial to translate these findings into effective clinical applications for breast cancer patients.

More Related Videos

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids05:39

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids

Published on: April 5, 2024

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...